SEER: Seer Inc Price to Sales

Symbol and logo of brand Seer Inc (SEER)

Against a backdrop of gradually depleting cash reserves due to high promotion costs, the price-to-sales ratio reflects market expectations, with the latest value recorded as 6.40. The strong pricing power of Seer, Inc. (SEER) is driven by the uniqueness of its protein analysis methods, while strategic partnerships with mass spectrometry leaders are accelerating biomedical research and the development of diagnostic equipment.

SEER (Seer) P/S Multiple history from 07/04/2022 to 11/13/2026

Analytical breakdowns for Seer Inc. (SEER)

- market price and analyst price targets:
Stock Quotes seer.bio|SEER - Analyst Consensus Forecast
- market capitalization information:
Market Value Seer Inc.|SEER - Enterprise Value
- shareholders' equity book value data:
Equity per Share Seer|SEER - Book Capitalization|Market Capitalization to Book Value seer.bio|SEER - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Seer, Inc.|SEER - Long-Term Debt to Capital|Short-Term Debt to Capital Seer Bio|SEER - Company Debts|Debt to Book Capitalization Ratio Seer Inc.|SEER - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Seer|Immediate Liquidity seer.bio
- net income and valuation multiples indicators:
SEER - Company Net Income|Projected Net Profit Seer, Inc.|SEER - Price to Earnings Ratio|Forward P/E Multiple Seer Inc|SEER - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Seer Inc.|SEER - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Seer|SEER - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months seer.bio|SEER - Earnings growth in current year|Expected net earnings per share growth next year Seer, Inc.
- issuer revenue and sales details:
SEER - Company Revenue|Company Revenue Forecast seer.bio|SEER - Market Cap to Revenue|Price to Expected Revenue Ratio Seer Inc.
Fundamental company analysis:seer.bio SEER
Original product of Seer Inc.

The P/S multiple serves as a key stress-testing tool for asset valuation, allowing for an assessment of the premium paid per unit of revenue relative to market capitalization. By analyzing the historical P/S value of Seer, Inc. (SEER), an investor correlates the revenue growth rates from Proteograph kit sales with the business valuation to timely recognize the risk of a correction should the scaling of the IT platform across global R&D centers slow down.

Who Seer, Inc. competes with

Market Cap to Revenue abbott.com ABT|P/S Multiple TMO (Thermo Fisher)|GE HealthCare Technologies Inc. (GEHC) - Price to Sales|Mettler-Toledo International Inc. - P/S Multiple|WAT (Waters Technologies) - Market Cap to Revenue Ratio|TECH: P/S Multiple|BRKR - Price-to-Revenue Coefficient|AZTA (Azenta) - P/S Multiple|Market Cap to Revenue Varex Imaging Corp (VREX)|P/S Multiple SMLR|P/S Multiple Butterfly Corp (BFLY)|Price-to-Revenue Ratio Mesa Laboratories, Inc. MLAB|quantum-si.com - Price-to-Revenue Ratio|NNOX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTRX (Quanterix Corp.)|MASS: P/S Multiple|Price to Sales CapsoVision (CV)|Price-to-Revenue Ratio MaxCyte, Inc.|RPID - Price-to-Revenue Multiple|Market Cap to Revenue HYPR (Hyperfine)|P/S Multiple FONAR Corp. (FONR)|P/S Multiple DXR (Daxor)|Price-to-Revenue Coefficient spectral-ai.com (MDAI)|VIVS - Price-to-Revenue Ratio|Price-to-Sales Ratio ACON|akoyabio.com (AKYA) - Price-to-Revenue Ratio|Market Cap to Revenue ThermoGenesis Holdings, Inc.|TLIS (Talis Biomedical Corp.) - P/S Multiple|Price to Sales T2 Biosystems Inc TTOO